{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:30:49Z","timestamp":1793968249885,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":2351,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Netherlands Organization for Scientific Research (NWO)","award":["017006041"],"award-info":[{"award-number":["017006041"]}],"id":[{"id":"https:\/\/ror.org\/04jsz6e67","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["IP11.44"],"award-info":[{"award-number":["IP11.44"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1111\/ajt.13691","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T09:16:35Z","timestamp":1451380595000},"page":"2085-2096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype\u2010Based With Body\u2010Weight\u2010Based Tacrolimus Dosing After Living Donor Kidney Transplantation"],"prefix":"10.1016","volume":"16","author":[{"given":"N.","family":"Shuker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bouamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Clahsen\u2010van Groningen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Rowshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Weimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.13691_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12019","article-title":"OPTN\/SRTR 2011 annual data report: Kidney","volume":"13","author":"Matas","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13691_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/ajt.13691_bib3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem"},{"key":"10.1111\/ajt.13691_bib4","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0090-9556(25)06862-X","article-title":"Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability","volume":"23","author":"Lampen","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ajt.13691_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/ajt.13691_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/ajt.13691_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/ajt.13059","article-title":"Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations","volume":"15","author":"Pallet","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13691_bib8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/clpt.2013.169","article-title":"Practicability of pharmacogenetics in transplantation medicine","volume":"95","author":"van Gelder","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","article-title":"The effect of CYP3A5 6986A > G and ABCB1 3435C > T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis","volume":"22","author":"Terrazzino","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"Suppl 3","key":"10.1111\/ajt.13691_bib11","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13691_bib12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1600-6143.2004.00435.x","article-title":"The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation","volume":"4","author":"MacPhee","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13691_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2010.42","article-title":"Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?","volume":"87","author":"van Gelder","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib14","unstructured":"Astellas Pharma U, Inc. PROGRAF\u00ae tacrolimus capsules, tacrolimus injection (for intravenous infusion only). 2009."},{"key":"10.1111\/ajt.13691_bib15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13691_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/ajt.13691_bib17","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"Van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"10.1111\/ajt.13691_bib18","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib19","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","article-title":"Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.13691_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids","volume":"56","author":"Hesselink","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ajt.13691_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/FPC.0b013e32834e1641","article-title":"The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients","volume":"22","author":"Birdwell","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/ajt.13691_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0b013e318200e991","article-title":"Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium","volume":"91","author":"Jacobson","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13691_bib23","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2217\/pgs.11.77","article-title":"The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients","volume":"12","author":"de Jonge","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1111\/ajt.13691_bib24","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"10.1111\/ajt.13691_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2125.2011.04039.x","article-title":"Dosing equation for tacrolimus using genetic variants and clinical factors","volume":"72","author":"Passey","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ajt.13691_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bcp.12076","article-title":"A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients","volume":"76","author":"Boughton","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ajt.13691_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/01.tp.0000259248.60448.8a","article-title":"Tacrolimus dose in black renal transplant recipients","volume":"83","author":"Vadivel","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13691_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/TP.0b013e3181609054","article-title":"A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype","volume":"85","author":"MacPhee","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13691_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/FPC.0b013e3282f75f88","article-title":"CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients","volume":"18","author":"Hesselink","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/ajt.13691_bib31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte\u2014an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for cyp3a5 genotype and tacrolimus dosing","volume":"98","author":"Bridwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ajt.13691_bib33","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.13691_bib34","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: Experience from the symphony study","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13691_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/ajt.12191","article-title":"Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials","volume":"13","author":"Bouamar","year":"2013","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.13691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.13691","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522009248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522009248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.13691\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:12:20Z","timestamp":1761628340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522009248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1600613522009248"],"URL":"https:\/\/doi.org\/10.1111\/ajt.13691","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype\u2010Based With Body\u2010Weight\u2010Based Tacrolimus Dosing After Living Donor Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.13691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}